← Leaderboards
Samir Parekh
Icahn School Of Medicine At Mount Sinai
$6,034,549
Attributed
$8,451,241
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,451,241 · 8
By mechanism
R01$6,264,775 · 3
R21$1,205,527 · 3
UH3$700,716 · 1
UH2$280,223 · 1
Top collaborators
- Michael Wang5 shared
- Ernesto Guccione3 shared
- Jordi Ochando3 shared
- Jian Jin1 shared
- Ivan Marazzi1 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Michael Schotsaert$3,271,645
- Ernesto Guccione$11,143,318
- Jordi Ochando$5,634,948
- Sarah E Millar$29,975,437
- Ivan Marazzi$13,016,096
Others in their field
Top investigators on “Sampling”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$522,319,685
- David R. Weir · University Of Michigan At Ann Arbor$421,002,438
- David Heimbrook · Leidos Biomedical Research, Inc.$410,224,927
- Eric S Lander · Whitehead Institute For Biomedical Res$395,613,296
- Richard A Gibbs · Baylor College Of Medicine$356,778,395
Research focus
SamplingRelapseTumorTranscriptome SequencingClinical TrialsMouse ModelMultiple MyelomaInsightDrug ResistanceIn VivoStandard Of CarePlasma CellsAnimal ModelEfficacy TestingBone MarrowNovel TherapeuticsChemotherapyPatient Derived Xenograft ModelRecommendationMalignant NeoplasmsGeneticMonitorBaseHeterogeneity
Grant awards (22)
Developing Lysine Methyltransferase SETD8 Selective Inhibitors for Treating Multiple Myeloma$701,330
R01 · FY2025 · CA
Implementation of a qPCR-based assay for the quantification of SARS-CoV-2-specific T cells in immunocompromised patients$350,358
UH3 · FY2025 · CA
Targeting SOX11 in Mantle Cell Lymphoma$534,024
R01 · FY2024 · CA · contact PI
Development of a multi-omic clinical decision platform to guide personalized therapy$520,055
R01 · FY2024 · CA · contact PI
Implementation of a qPCR-based assay for the quantification of SARS-CoV-2-specific T cells in immunocompromised patients$350,358
UH3 · FY2024 · CA
Targeting SOX11 in Mantle Cell Lymphoma$550,887
R01 · FY2023 · CA · contact PI
Development of a multi-omic clinical decision platform to guide personalized therapy$527,492
R01 · FY2023 · CA · contact PI
Implementation of a qPCR-based assay for the quantification of SARS-CoV-2-specific T cells in immunocompromised patients$280,223
UH2 · FY2023 · CA
Development of a multi-omic clinical decision platform to guide personalized therapy$80,387
R01 · FY2023 · CA · contact PI
Targeting SOX11 in Mantle Cell Lymphoma$550,887
R01 · FY2022 · CA · contact PI
Development of a multi-omic clinical decision platform to guide personalized therapy$525,071
R01 · FY2022 · CA · contact PI
Development of a multi-omic clinical decision platform to guide personalized therapy$82,028
R01 · FY2022 · CA · contact PI
Targeting SOX11 in Mantle Cell Lymphoma$562,130
R01 · FY2021 · CA · contact PI
Development of a multi-omic clinical decision platform to guide personalized therapy$531,246
R01 · FY2021 · CA · contact PI
Targeting SOX11 in Mantle Cell Lymphoma$579,503
R01 · FY2020 · CA · contact PI
Development of a multi-omic clinical decision platform to guide personalized therapy$519,735
R01 · FY2020 · CA · contact PI
Patient-Specific Mutation-Derived Tumor Neoantigens as Targets for Cancer Immunotherapy in Smoldering Multiple Myeloma$178,800
R21 · FY2019 · CA · contact PI
Patient-Specific Mutation-Derived Tumor Neoantigens as Targets for Cancer Immunotherapy in Smoldering Multiple Myeloma$221,198
R21 · FY2018 · CA · contact PI
A network-based approach for personalized treatment of Multiple Myeloma$184,331
R21 · FY2018 · CA · contact PI
A network-based approach for personalized treatment of Multiple Myeloma$221,198
R21 · FY2017 · CA · contact PI
Epigenomic determinants of clinical outcomes in MCL patients treated on E1405$178,802
R21 · FY2014 · CA · contact PI
Epigenomic determinants of clinical outcomes in MCL patients treated on E1405$221,198
R21 · FY2013 · CA · contact PI